Authors/Disclosures
|
Virginia Sturm, PhD
|
Dr. Sturm has nothing to disclose. |
|
Fahd Sultan, MD
(University of Oklahoma Health Sciences Center)
|
Dr. Sultan has nothing to disclose. |
|
Marc Sollberger, MD
|
No disclosure on file |
|
William W. Seeley, MD
|
Dr. Seeley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GLG Council. Dr. Seeley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Guidepoint Global Consulting. Dr. Seeley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BridgeBio. Dr. Seeley has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Seeley has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lyterian Therapeutics. The institution of Dr. Seeley has received research support from NIH. The institution of Dr. Seeley has received research support from Rainwater Charitable Foundation. The institution of Dr. Seeley has received research support from Bluefield Project to Cure FTD. The institution of Dr. Seeley has received research support from Chan-Zuckerberg Initiative. |
|
Katherine P. Rankin, PhD
(University of California San Francisco)
|
The institution of Dr. Rankin has received research support from Marcus Foundation. |
|
Howard J. Rosen, MD
(UCSF)
|
Dr. Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai Pharmaceuticals. Dr. Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. The institution of Dr. Rosen has received research support from NIH. The institution of Dr. Rosen has received research support from State of CA. Dr. Rosen has a non-compensated relationship as a Consultant with Alector that is relevant to AAN interests or activities. Dr. Rosen has a non-compensated relationship as a Consultant with Prevail Therapeutics that is relevant to AAN interests or activities. Dr. Rosen has a non-compensated relationship as a consultant with Alchemab that is relevant to AAN interests or activities. |
|
Jodie Haselkorn, MD, MPH
(University of Washington/Veteran'S Administration)
|
No disclosure on file |
|
Bruce L. Miller, MD, FAAN
(University of California, San Francisco)
|
Dr. Miller has nothing to disclose. |
|
|
No disclosure on file |